Due diligence is an important process that helps your team comprehensively understand the technology platform and science behind an asset, identify potential risks and gaps, and ensure an efficient product development pathway. Pearl Pathways offers expertise for new product in-licensing/out-licensing, acquisition or divesting opportunities. This can range from a new formulation or chemical entity to a new technology platform. Our expert team leverages decades of industry experience to help companies that need to perform an in-depth analysis of a technology platform to ensure their product has a viable regulatory strategy and pathway. An evaluation of CMC, non-clinical, and clinical development strategies will be conducted by our advisors as well. We will also provide an assessment of appropriate development studies and budgetary estimates necessary for regulatory agency approval.
Mergers and acquisitions in the life science industry can be chaotic. Costly surprises are seemingly inevitable, unless a careful due diligence process is followed. Pearl Pathways is here to help. Our advisors’ tenure in the biopharmaceutical, pharmaceutical, medical device, and diagnostic industries allow them to efficiently assess all successful issues at stake. Our experts will assess all aspects of an asset to generate a thorough report of findings which can be a crucial step to making the correct business decisions for a successful merger or aquisition. Our due diligence reviews are not limited to the life science companies involved; we also commonly advise venture capital and private equity firms, lenders, and other investors.